Although PD-L1 has not consistently emerged as a predictive biomarker in the curative setting based on randomized trials, it is now recommended by NCCN guidelines in localized adenocarcinomas to consider the addition of immunotherapy to perioperative chemotherapy, highlighting its increasing relevance in clinical practice [25]. Here, CD274 is linked to adenocarcinoma.